Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis products.
Source: https://www.cnbc.com/2025/02/12/biogen- ... -2024.html
Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short
